跳至主要内容
临床试验/NCT01114477
NCT01114477已完成不适用

NeuroStar TMS Therapy System: Data Management, Analysis and Reporting Format for Clinical Treatment Utilization and Outcomes (Protocol no. 19-50001-000,Rev D

Neuronetics44 个研究点 分布在 1 个国家目标入组 307 人开始时间: 2010年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Neuronetics
入组人数
307
试验地点
44
主要终点
Total Score on the Patient Health Questionnaire 9-Item (PHQ-9)

研究概览

简要总结

The major objective of this observational study is to describe clinical outcomes of patients receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Major Depressive Disorder

排除标准

  • Contraindications to treatment with TMS

结局指标

主要结局

Total Score on the Patient Health Questionnaire 9-Item (PHQ-9)

时间窗: Baseline and 6 weeks

The primary outcome measure will reported as the change from baseline through 6 weeks for the total score on the PHQ-9.

次要结局

  • Health Resource Utilization Questionnaire (HRU)(Baseline, 6 weeks, and 12 Months)
  • Total score for the Clinical Global Impressions-Severity (CGI-S)(Baseline, 6 weeks and 12 Months)
  • Total Score for the EuroQol Questionnaire (EQ-5D)(Baseline, 6 weeks, and 12 Months.)
  • Short Form 36-Item Questionnaire(SF-36) Individual Factor Scores and General Medical and Mental Health Composite Scores(Baseline, 6 weeks, and 12 Months.)
  • Total score for the Inventory of Depressive Symptoms-Self Report (IDS-SR)(Baseline, 6 weeks and 12 Months)

研究者

发起方
Neuronetics
申办方类型
Other
责任方
Sponsor

研究点 (44)

Loading locations...

相似试验

NeuroStar TMS Therapy System: Utilization and... | 临床试验